Comparation Between Included and Rejected Series for the Final Statistical Analysis
| . | Excluded (%) . | Included (%) . | P . |
|---|---|---|---|
| Cases | 70 | 140 | |
| Age (yr) (mean ± SD) | 38.6 ± 18.3 | 37.2 ± 17.5 | .5820* |
| Gender | |||
| Male | 37 (52.85) | 93 (66.42) | .0563† |
| Female | 33 (47.14) | 47 (33.57) | .0563† |
| Response to initial treatment | |||
| Complete remission | 55 (78.57) | 111 (79.28) | .8283† |
| Treatment failure | 15 (21.42) | 28 (20.00) | .8283† |
| Overall survivall | |||
| Mean ± SD (mo) | 60.6 ± 45.3 | 53.7 ± 34.0 | .2314‡ |
| Actuarial status | |||
| Alive | 46 (65.71) | 98 (70.00) | .5283† |
| Deaths | 18 (25.71) | 28 (20.00) | .3453† |
| Missing cases | 6 (8.57) | 14 (10.00) | .7395† |
| Histopathological type | |||
| Lymphocytic predominance | 6 (8.57) | 13 (9.28) | .8649† |
| Nodular sclerosis | 37 (52.85) | 74 (52.85) | 1.0000† |
| Mixed cellularity | 22 (31.42) | 49 (35.00) | .6060† |
| Lymphocytic depletion | 5 (7.14) | 4 (2.85) | .1483† |
| Stage | |||
| I | 5 (7.14) | 24 (17.14) | .0510† |
| II | 32 (45.71) | 49 (35.00) | .1327† |
| III | 20 (28.57) | 39 (27.85) | .9135† |
| IV | 13 (18.57) | 28 (20.00) | .8055† |
| . | Excluded (%) . | Included (%) . | P . |
|---|---|---|---|
| Cases | 70 | 140 | |
| Age (yr) (mean ± SD) | 38.6 ± 18.3 | 37.2 ± 17.5 | .5820* |
| Gender | |||
| Male | 37 (52.85) | 93 (66.42) | .0563† |
| Female | 33 (47.14) | 47 (33.57) | .0563† |
| Response to initial treatment | |||
| Complete remission | 55 (78.57) | 111 (79.28) | .8283† |
| Treatment failure | 15 (21.42) | 28 (20.00) | .8283† |
| Overall survivall | |||
| Mean ± SD (mo) | 60.6 ± 45.3 | 53.7 ± 34.0 | .2314‡ |
| Actuarial status | |||
| Alive | 46 (65.71) | 98 (70.00) | .5283† |
| Deaths | 18 (25.71) | 28 (20.00) | .3453† |
| Missing cases | 6 (8.57) | 14 (10.00) | .7395† |
| Histopathological type | |||
| Lymphocytic predominance | 6 (8.57) | 13 (9.28) | .8649† |
| Nodular sclerosis | 37 (52.85) | 74 (52.85) | 1.0000† |
| Mixed cellularity | 22 (31.42) | 49 (35.00) | .6060† |
| Lymphocytic depletion | 5 (7.14) | 4 (2.85) | .1483† |
| Stage | |||
| I | 5 (7.14) | 24 (17.14) | .0510† |
| II | 32 (45.71) | 49 (35.00) | .1327† |
| III | 20 (28.57) | 39 (27.85) | .9135† |
| IV | 13 (18.57) | 28 (20.00) | .8055† |